Literature DB >> 33381644

Nausea-Induced Conditioned Gaping Reactions in Rats Produced by High-Dose Synthetic Cannabinoid, JWH-018.

Marieka V DeVuono1, Kelly M Hrelja1, Gavin N Petrie2,3, Cheryl L Limebeer1, Erin M Rock1, Matthew N Hill2,3, Linda A Parker1.   

Abstract

Introduction: Cannabinoid hyperemesis syndrome is becoming a more prominently reported side effect of cannabis containing high-dose Δ9-tetrahydrocannabinol (THC) and designer cannabinoid drugs such as "Spice." One active ingredient that has been found in "Spice" is 1-pentyl-3-(1-naphthoyl)indole (JWH-018), a synthetic full agonist of the cannabinoid 1 (CB1) receptor. In this study, we evaluated the potential of different doses of JWH-018 to produce conditioned gaping in rats, an index of nausea. Materials and
Methods: Rats received 3 daily conditioning trials in which saccharin was paired with JWH-018 (0.0, 0.1, 1, and 3 mg/kg, intraperitoneal [i.p.]). Then the potential of pretreatment with the CB1 antagonist, rimonabant (SR), to prevent JWH-018-induced conditioned gaping was determined. To begin to understand the potential mechanism underlying JWH-018-induced nausea, serum collected from trunk blood was subjected to a corticosterone (CORT) analysis in rats receiving three daily injections with vehicle (VEH) or JWH-018 (3 mg/kg).
Results: At doses of 1 and 3 mg/kg (i.p.), JWH-018 produced nausea-like conditioned gaping reactions. The conditioned gaping produced by 3 mg/kg JWH-018 was reversed by pretreatment with rimonabant, which did not modify gaping on its own. Treatment with JWH-018 elevated serum CORT levels compared to vehicle-treated rats. Conclusions: As we have previously reported with high-dose THC, JWH-018 produced conditioned gaping in rats, reflective of a nausea effect mediated by its action on CB1 receptors and accompanied by elevated CORT, reflective of hypothalamic-pituitary-adrenal (HPA) activation. Copyright 2020, Mary Ann Liebert, Inc., publishers.

Entities:  

Keywords:  HPA axis; cannabinoid 1 receptor; corticosterone; emesis; nausea; synthetic cannabinoid

Year:  2020        PMID: 33381644      PMCID: PMC7759265          DOI: 10.1089/can.2019.0103

Source DB:  PubMed          Journal:  Cannabis Cannabinoid Res        ISSN: 2378-8763


  61 in total

1.  Convulsions associated with the use of a synthetic cannabinoid product.

Authors:  Aaron B Schneir; Todd Baumbacher
Journal:  J Med Toxicol       Date:  2012-03

Review 2.  Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids.

Authors:  Kathryn A Seely; Jeff Lapoint; Jeffery H Moran; Liana Fattore
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-04-26       Impact factor: 5.067

3.  Conditioned gaping produced by high dose Δ9-tetrahydracannabinol: Dysregulation of the hypothalamic endocannabinoid system.

Authors:  Marieka V DeVuono; Kelly M Hrelja; Lauren Sabaziotis; Alex Rajna; Erin M Rock; Cheryl L Limebeer; David M Mutch; Linda A Parker
Journal:  Neuropharmacology       Date:  2018-09-07       Impact factor: 5.250

4.  Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew.

Authors:  N A Darmani
Journal:  Pharmacol Biochem Behav       Date:  2001 May-Jun       Impact factor: 3.533

5.  Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A.

Authors:  N A Darmani
Journal:  Neuropsychopharmacology       Date:  2001-02       Impact factor: 7.853

6.  The effects of cannabidiol and tetrahydrocannabinol on motion-induced emesis in Suncus murinus.

Authors:  Nina L Cluny; Robert J Naylor; Brian A Whittle; Farideh A Javid
Journal:  Basic Clin Pharmacol Toxicol       Date:  2008-08       Impact factor: 4.080

7.  Biphasic nature of the effects of delta9-tetrahydrocannabinol on body temperature and brain amines of the rat.

Authors:  D A Taylor; M R Fennessy
Journal:  Eur J Pharmacol       Date:  1977-11-15       Impact factor: 4.432

8.  Endocannabinoid-related lipids are increased during an episode of cyclic vomiting syndrome.

Authors:  T Venkatesan; Y Zadvornova; H Raff; C J Hillard
Journal:  Neurogastroenterol Motil       Date:  2016-04-20       Impact factor: 3.598

9.  A case of cannabinoid hyperemesis syndrome caused by synthetic cannabinoids.

Authors:  Christopher Y Hopkins; Brandi L Gilchrist
Journal:  J Emerg Med       Date:  2013-07-26       Impact factor: 1.484

Review 10.  Cyclic vomiting syndrome: diagnostic approach and current management strategies.

Authors:  William J Hayes; Deidra VanGilder; Joseph Berendse; Michael D Lemon; John A Kappes
Journal:  Clin Exp Gastroenterol       Date:  2018-02-26
View more
  3 in total

1.  Cannabidiol Interferes with Establishment of Δ9-Tetrahydrocannabinol-Induced Nausea Through a 5-HT1A Mechanism.

Authors:  Marieka V DeVuono; Olivia La Caprara; Gavin N Petrie; Cheryl L Limebeer; Erin M Rock; Matthew N Hill; Linda A Parker
Journal:  Cannabis Cannabinoid Res       Date:  2020-12-21

2.  Stroboscopic lighting with intensity synchronized to rotation velocity alleviates motion sickness gastrointestinal symptoms and motor disorders in rats.

Authors:  Yuqi Mao; Leilei Pan; Wenping Li; Shuifeng Xiao; Ruirui Qi; Long Zhao; Junqin Wang; Yiling Cai
Journal:  Front Integr Neurosci       Date:  2022-07-28

3.  Sex and stressor modality influence acute stress-induced dynamic changes in corticolimbic endocannabinoid levels in adult Sprague Dawley rats.

Authors:  Haley A Vecchiarelli; Maria Morena; Tiffany T Y Lee; Andrei S Nastase; Robert J Aukema; Kira D Leitl; J Megan Gray; Gavin N Petrie; Kristin J Tellez-Monnery; Matthew N Hill
Journal:  Neurobiol Stress       Date:  2022-07-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.